© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#ASH 2019

illustrarion of blood cells
Targeted Combos Deal Double Blow Against Chronic Lymphocytic Leukemia
CAR-T Therapies Show Promise for More Blood Cancers
researchers working in the lab
Click Here for More Conferences

Gimme Shelter: CRISPR Hides Healthy Cells From Leukemia Drug

In mouse study, gene-edited cells stay safe as immunotherapy attacks cancer
When CC-486 (purple dots) inserts into the DNA of cancer cells (blue/green), it prevents the DNA from getting modified with chemicals called methyl groups (red/orange circles). This may help reactivate certain genes and help kill the cancer cells.

Maintenance Therapy With CC-486 Extends Survival of Adults With AML

The drug may represent a “fundamental building block for new combinations that will hopefully have transformative potential.”

Try, Try Again: Can a Second Dose of CAR-T Cells Succeed When the First Fails?

First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options.

Hepatitis C Cure Improves Lymphoma Treatment Outcomes

Study results underline the importance of treating hepatitis C virus.
Blinatumomab binds to CD19, a protein on the surface of B-ALL cells, and CD3, a protein on T cells, helping the T cells recognize and kill the cancer cells.

Blincyto Improves Outcomes for Some Children With Relapsed Leukemia

Investigators wanted to see if blinatumomab could increase survival rates free from leukemia and be less toxic than intensive chemotherapy.
Multiple myeloma cells

CAR-T Therapies for Multiple Myeloma Show High Response Rates

90% to 100% of study participants achieved complete or partial responses to treatment.

Hot topics

ASH 2018
test tubes in lab eye dropper
ASH 2017
Red and white blood cells

FDA Approves New Treatment for Chronic Lymphocytic Leukemia

Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Advertisement
Features
Newsfeed